By IBTimes - Friday, August 19 2011
A small Massachusetts company announced it has successfully sequenced the genome of a marijuana plant, a move that may bring scientists one step closer to understanding the therapeutic benefits of cannabis, including its potential to treat cancer and inflammatory diseases.
Medicinal Genomics published the raw sequence strings on Amazon.com's EC2 cloud computing system. The findings, which have not yet undergone peer review, found that the DNA sequence of the plant has 84 other compounds that could fight pain or possibly shrink tumors.
Kevin McKernan, the founder and chief executive officer of Medicinal Genomics, told NPR that he has spent most of his career studying tumors, and became interested in marijuana's healing properties after several friends with cancer asked him about its medicinal benefits. After hearing about a drug called Sativex, a cannabis-derived medication developed by a German pharmaceutical company that treats muscle stiffness, McKernan became more committed to investigating emerging medical research on the plant.
Sativex contains tetrahydrocannabinol, commonly known as THC, and another cannabinoid called CBD, which reportedly negates some of the psychoactive effects of THC. The drug is now available in the
United Kingdom, Spain and
Germany and is currently in trials to see if it can successfully treat cancer pain.
- Article Originally from International Business Times.
http://www.cannabisculture.com/v2/co...rijuana-Genome
Bookmarks